Empagliflozin in Acute Myocardial Infarction Reduces No-Reflow and Preserves Cardiac Function by Preventing Endothelial Damage

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2025-01-01 DOI:10.1016/j.jacbts.2024.08.003

Panagiota Efstathia Nikolaou PhD , Lara S.F. Konijnenberg MD, PhD , Ioannis V. Kostopoulos PhD , Marios Miliotis PhD , Nikolaos Mylonas MSc , Anastasios Georgoulis PhD , George Pavlidis MD, PhD , Carolien T.A. Kuster Msc , Vince P.A. van Reijmersdal Msc , Tom T.J. Luiken Msc , Anna Agapaki PhD , Rona Roverts PhD , Nikolaos Orologas PhD , Dimitris Grigoriadis PhD , Gaëtan Pallot PhD , Pierre Boucher MSc , Nikolaos Kostomitsopoulos PhD , Michael Paul Pieper PhD , Stéphane Germain PhD , Yannis Loukas PhD , Ioanna Andreadou PhD

{"title":"Empagliflozin in Acute Myocardial Infarction Reduces No-Reflow and Preserves Cardiac Function by Preventing Endothelial Damage","authors":"Panagiota Efstathia Nikolaou PhD , Lara S.F. Konijnenberg MD, PhD , Ioannis V. Kostopoulos PhD , Marios Miliotis PhD , Nikolaos Mylonas MSc , Anastasios Georgoulis PhD , George Pavlidis MD, PhD , Carolien T.A. Kuster Msc , Vince P.A. van Reijmersdal Msc , Tom T.J. Luiken Msc , Anna Agapaki PhD , Rona Roverts PhD , Nikolaos Orologas PhD , Dimitris Grigoriadis PhD , Gaëtan Pallot PhD , Pierre Boucher MSc , Nikolaos Kostomitsopoulos PhD , Michael Paul Pieper PhD , Stéphane Germain PhD , Yannis Loukas PhD , Ioanna Andreadou PhD","doi":"10.1016/j.jacbts.2024.08.003","DOIUrl":null,"url":null,"abstract":"<div><div>Empagliflozin treatment before acute myocardial infarction mainly targets the endothelial cell transcriptome. Empagliflozin treatment before and after myocardial infarction decreased no reflow and microvascular injury, leading to reduced infiltration of inflammatory cells, reduced infarct size, and improved cardiac function in mice. In diabetic patients receiving empagliflozin after myocardial infarction, perfused boundary region, flow-mediated dilation, and global longitudinal strain were improved.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 1","pages":"Pages 43-61"},"PeriodicalIF":8.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X24002948","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Empagliflozin treatment before acute myocardial infarction mainly targets the endothelial cell transcriptome. Empagliflozin treatment before and after myocardial infarction decreased no reflow and microvascular injury, leading to reduced infiltration of inflammatory cells, reduced infarct size, and improved cardiac function in mice. In diabetic patients receiving empagliflozin after myocardial infarction, perfused boundary region, flow-mediated dilation, and global longitudinal strain were improved.

查看原文本刊更多论文

恩格列净治疗急性心肌梗死可通过预防内皮损伤减少无回流并保护心功能

急性心肌梗死前的恩格列净治疗主要针对内皮细胞转录组。心肌梗死前后接受恩格列净治疗可减少无回流和微血管损伤，从而减少炎症细胞浸润，缩小梗死面积，改善小鼠心功能。糖尿病患者在心肌梗死后接受恩格列净治疗，灌注边界区、血流介导的扩张和整体纵向应变均得到改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.